The Gut–Bone Axis: A Systematic Review on the Potential Intervention Pathways for Bone Health
Abstract
1. Introduction
1.1. Background
1.2. Osteoporosis Disease
1.3. The Gut–Bone and Gut–Brain–Bone Axes
2. Scope and Search Strategies in the Semi-Automated Systematic Review
2.1. Automating a Systematic Review
2.2. Databases and Search Strategies
| (microbiota [Title/Abstract] OR microbiome [Title/Abstract]) AND (Bone [Title/Abstract]) | Query 1. Search performed in PubMed to identify articles. |
2.3. Generation of Keywords
2.4. Specific Criteria
2.5. Iterative Filtering for Classification
2.6. Data Extraction
2.7. Quality Control
3. Results and Discussion
3.1. Potential Targets Within the Gut–Bone Axis
3.1.1. Native Bacteria Supporting Bone Formation
3.1.2. Native Bacteria Promoting Bone Resorption
3.1.3. Metabolites Involved in Bone Health
SCFAs
Vitamins and Minerals
Amino Acid-Derived Metabolites
Hormones and Growth Factors
Inflammatory and Toxic Metabolites
3.1.4. Probiotics as Potential Intervention Treatment for Osteoporosis and Bone Related Diseases
3.1.5. Case of Study: Lactobacillus rhamnosus GG (LGG)
3.2. Potential Targets Within the Gut–Brain–Bone Axis
3.3. Bone ECM Proteins as Mediators of the Gut–(Brain)–Bone Axes
3.3.1. Osteopontin
3.3.2. Cathepsin K
| Metabolic Pathway | Effect in Bone Health and Metabolites Involved | Related Microbiota | References |
|---|---|---|---|
| Osteopontin | |||
| NF-B Signaling | Promotes osteoclastogenesis by activating osteoclasts, leading to bone resorption. Inflammatory cytokines like TNF- enhance the expression of osteopontin, further promoting resorption. | Lactobacillus reuteri, Bifidobacteria | [92] |
| RANK/RANKL Signaling | Facilitates osteoclast differentiation and activation, leading to bone resorption. Osteopontin binds to integrin receptors on osteoclasts, enhancing their adhesion to bone matrix. | Faecalibacterium prausnitzii, Lactobacillus reuteri | [48,92] |
| MAPK Pathway | Regulates osteoclast activity and expression of osteopontin, contributing to bone resorption. It also impacts osteoblast activity through the production of growth factors like TGF-. | Faecalibacterium prausnitzii, Dialister | [48] |
| TGF-/BMP Pathway | Modulates osteoblast differentiation and activity, promoting bone formation. Osteopontin acts as an anti-apoptotic factor for osteoblasts, favoring continuous bone formation. | Faecalibacterium prausnitzii, Bifidobacteria | [93] |
| WNT Signaling | Enhances osteoblast differentiation and bone formation through the regulation of gene expression related to bone development. Osteopontin is involved in maintaining osteoblast survival. | Lactobacillus reuteri, Bifidobacteria | [48,93] |
| TAZ/IHH Pathway | Contributes to the regulation of osteogenesis and the maintenance of bone matrix, supporting the role of osteopontin in bone formation. | Faecalibacterium prausnitzii | [48] |
| Cathepsin K | |||
| Inflammation induced by obesity | TNF-, IL-1: These cytokines increase Cathepsin K activity, enhancing collagen degradation and osteoclast differentiation, leading to increased bone resorption and decreased BMD. | Promotes osteoclastogenesis, leading to increased bone resorption and decreased BMD. | [88] |
| Signaling by LPS | IL-1, IL-6, TNF-: LPS induces these cytokines, which stimulate Cathepsin K activity, boosting osteoclast activity and accelerating bone matrix breakdown. | Promotes osteoclastogenesis, leading to increased bone resorption. | [91] |
| MAMPs | TRAP, MMP-9, Runx2, osterix: SCFAs, products of bacterial metabolism, inhibit osteoclast differentiation at low doses, reducing Cathepsin K activity, thus supporting bone formation and promoting osteogenic activity. | Promotes osteogenic activity, providing a protective effect on bone health. | [91] |
4. Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sasso, J.M.; Ammar, R.M.; Tenchov, R.; Lemmel, S.; Kelber, O.; Grieswelle, M.; Qiongqiong, A.Z. Gut Microbiome-Brain Alliance: A Landscape View into Mental and Gastrointestinal Health and Disorders. ACS Chem. Neurosci. 2023, 14, 1717–1763. [Google Scholar] [CrossRef]
- Fukasawa, N.; Tsunoda, J.; Sunaga, S.; Kiyohara, H.; Nakamoto, N.; Teratani, T.; Mikami, Y.; Kanai, T. The gut-organ axis: Clinical aspects and immune mechanisms. Allergol. Int. 2025, 74, 197–209. [Google Scholar] [CrossRef]
- Che, H.; Gao, Y.; Xu, Y.; Xu, H.; Eils, R.; Tian, M. Organ cross-talk: Molecular mechanisms, biological functions, and therapeutic interventions for diseases. Signal Transduct. Target. Ther. 2026, 11, 8. [Google Scholar] [CrossRef] [PubMed]
- Han, D.; Wang, W.; Gong, J.; Ma, Y.; Li, Y. Microbiota metabolites in bone: Shaping health and Confronting disease. Heliyon 2024, 10, e28435. [Google Scholar] [CrossRef]
- Fontcuberta-Rigo, M.; Nakamura, M.; Puigbò, P. Phylobone: A comprehensive database of bone extracellular matrix proteins in human and model organisms. Bone Res. 2023, 11, 44. [Google Scholar] [CrossRef]
- Shimochi, S.; Brunet, C.; Fontcuberta-Rigo, M.; Hrovat, K.; Puigbò, P.; Nakamura, M. Bone mechano-response is driven by locomotion transitions during vertebrate evolution. Commun. Biol. 2025, 9, 31. [Google Scholar] [CrossRef]
- Li, S.; Cai, X.; Guo, J.; Li, X.; Li, W.; Liu, Y.; Mengchun, Q. Cell communication and relevant signaling pathways in osteogenesis-angiogenesis coupling. Bone Res. 2025, 13, 45. [Google Scholar] [CrossRef]
- Panait, C.; D’Amelio, P. Advancing care: Optimizing osteoporosis treatment in the older and oldest old population. Aging Clin. Exp. Res. 2025, 37, 123. [Google Scholar] [CrossRef] [PubMed]
- Sözen, T.; Özışık, L.; Başaran, N.Ç. An overview and management of osteoporosis. Eur. J. Rheumatol. 2017, 4, 46–56. [Google Scholar] [CrossRef] [PubMed]
- Noh, J.-Y.; Yang, Y.; Jung, H. Molecular mechanisms and emerging therapeutics for osteoporosis. Int. J. Mol. Sci. 2020, 21, 7623. [Google Scholar] [CrossRef]
- Zhu, M.; Zhang, X.; Zhang, J.; Chen, J.; Liang, L. The gut-bone axis: Mechanisms through which oleic acid regulates bone metabolism and its potential in preventing and treating osteoporosis. Front. Nutr. 2026, 13, 1745125. [Google Scholar] [CrossRef]
- McCabe, L.; Britton, R.A.; Parameswaran, N. Prebiotic and probiotic regulation of bone health: Role of the intestine and its microbiome. Curr. Osteoporos. Rep. 2015, 13, 363–371. [Google Scholar] [CrossRef]
- Chu, X.; Xing, H.; Chao, M.; Xie, P.; Jiang, L. Gut microbiota modulation in osteoporosis: Probiotics, prebiotics, and natural compounds. Metabolites 2025, 15, 301. [Google Scholar] [CrossRef] [PubMed]
- Shi, H.; Huang, L.; Zhang, J.H.; Shen, C.; Zhang, N.; Lv, C.; Shao, L.; Mengyao, L.; Zijin, S.; Liang, S.; et al. Gut Microbiota Regulates Brain-Bone Axis to Influence Osteoporosis Pathogenesis and Treatment. Research 2026, 9, 1178. [Google Scholar] [CrossRef]
- Wu, J.; Zhang, S.; Wu, J.; Luan, Y.; Yao, X.; Xu, B.; Wang, Y.; Sheng, Y.; Xue, Y.; Ren, Y. Targeting the gut-bone axis through exercise: A novel approach to osteoporosis prevention and treatment (Review). Int. J. Mol. Med. 2026, 57, 1–15. [Google Scholar] [CrossRef]
- Amend, S.R.; Uluckan, O.; Hurchla, M.; Leib, D.; Novack, D.V.; Silva, M.; Frazier, W.; Weilbaecher, K.N. Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts. J. Bone Miner. Res. 2015, 30, 106–115. [Google Scholar] [CrossRef] [PubMed]
- Li, R.; Miao, Z.; Liu, Y.; Chen, X.; Wang, H.; Su, J.; Chen, J. The Brain-Gut-Bone Axis in Neurodegenerative Diseases: Insights, Challenges, and Future Prospects. Adv. Sci. 2024, 11, e2307971. [Google Scholar] [CrossRef]
- Liu, C.; Yang, Y.-N.; Guo, S.; Cao, Y.; Wang, L.-N.; Wu, C. Gut microbiota-mediated regulation of skeletal development: A review of mechanistic analysis and interventional strategies. J. Adv. Res. 2025, 82, 397–410. [Google Scholar] [CrossRef] [PubMed]
- Cong, B.; Zhang, H. The effects of combined calcium and vitamin D supplementation on bone mineral density and fracture risk in postmenopausal women with osteoporosis: A systematic review and meta-analysis of randomized controlled trials. BMC Musculoskelet. Disord. 2025, 26, 928. [Google Scholar] [CrossRef]
- Han, H.; Yan, H.; King, K.Y. Broad-Spectrum Antibiotics Deplete Bone Marrow Regulatory T Cells. Cells 2021, 10, 277. [Google Scholar] [CrossRef]
- Peng, Y.; Zhong, Z.; Huang, C.; Wang, W. The effects of popular diets on bone health in the past decade: A narrative review. Front. Endocrinol. 2023, 14, 1287140. [Google Scholar] [CrossRef] [PubMed]
- Puigbò, P.; Leino, L.I.; Rainio, M.J.; Saikkonen, K.; Saloniemi, I.; Helander, M. Does glyphosate affect the human microbiota? Life 2022, 12, 707. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Zhang, H.; Du, W.; Hu, J.; Quan, R. Association between urinary glyphosate exposure and bone mineral density in adults. Medicine 2023, 102, e36506. [Google Scholar] [CrossRef]
- Zhang, J.; Mai, Q.; Di, D.; Zhou, H.; Zhang, R.; Wang, Q. Potential roles of gut microbiota in metal mixture and bone mineral density and osteoporosis risk association: An epidemiologic study in Wuhan. Environ. Sci. Pollut. Res. Int. 2023, 30, 117201–117213. [Google Scholar] [CrossRef]
- Lyu, Z.; Hu, Y.; Guo, Y.; Liu, D. Modulation of bone remodeling by the gut microbiota: A new therapy for osteoporosis. Bone Res. 2023, 11, 31. [Google Scholar] [CrossRef]
- Chen, M.; Wang, J.; Yang, Y.; He, Y.; Li, L. The interplay of estrogen, gut microbiome, and bone immunity in osteoporosis. Cell Commun. Signal. 2025, 23, 516. [Google Scholar] [CrossRef]
- Xie, X.; Liu, H.; Wan, K.; Li, J.; Qi, P. The gut microbiota in osteoporosis: Dual roles and therapeutic prospects. Front. Immunol. 2025, 16, 1617459. [Google Scholar] [CrossRef]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Syst. Rev. 2021, 10, 89. [Google Scholar] [CrossRef]
- Uman, L.S. Systematic reviews and meta-analyses. J. Can. Acad. Child. Adolesc. Psychiatry 2011, 20, 57–59. [Google Scholar]
- Rowland, I.; Gibson, G.; Heinken, A.; Scott, K.; Swann, J.; Thiele, I.; Tuohy, K. Gut microbiota functions: Metabolism of nutrients and other food components. Eur. J. Nutr. 2018, 57, 1–24. [Google Scholar] [CrossRef] [PubMed]
- Behera, J.; Ison, J.; Tyagi, S.C.; Tyagi, N. The role of gut microbiota in bone homeostasis. Bone 2020, 135, 115317. [Google Scholar] [CrossRef]
- Li, J.; Ho, W.T.P.; Liu, C.; Chow, S.K.-H.; Ip, M.; Yu, J.; Wong, H.S.; Cheung, W.-H.; Sung, J.J.Y.; Wong, R.M.Y. The role of gut microbiota in bone homeostasis. Bone Jt. Res. 2021, 10, 51–59. [Google Scholar] [CrossRef] [PubMed]
- Zhong, X.; Zhang, F.; Yin, X.; Cao, H.; Wang, X.; Liu, D.; Chen, J.; Chen, X. Bone Homeostasis and Gut Microbial-Dependent Signaling Pathways. J. Microbiol. Biotechnol. 2021, 31, 765–774. [Google Scholar] [CrossRef]
- Wallimann, A.; Magrath, W.; Thompson, K.; Moriarty, T.; Richards, R.G.; Akdis, C.A.; O’Mahony, L.; Hernandez, C.J. Gut microbial-derived short-chain fatty acids and bone: A potential role in fracture healing. Eur. Cell Mater. 2021, 41, 454–470. [Google Scholar] [CrossRef]
- den Besten, G.; van Eunen, K.; Groen, A.K.; Venema, K.; Reijngoud, D.-J.; Bakker, B.M. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 2013, 54, 2325–2340. [Google Scholar] [CrossRef]
- Dalile, B.; Van Oudenhove, L.; Vervliet, B.; Verbeke, K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 461–478. [Google Scholar] [CrossRef]
- Dar, H.Y.; Shukla, P.; Mishra, P.K.; Anupam, R.; Mondal, R.K.; Tomar, G.B.; Sharma, V.; Srivastava, R.K. Lactobacillus acidophilus inhibits bone loss and increases bone heterogeneity in osteoporotic mice via modulating Treg-Th17 cell balance. Bone Rep. 2018, 8, 46–56. [Google Scholar] [CrossRef]
- Xu, Q.; Li, D.; Chen, J.; Yang, J.; Yan, J.; Xia, Y.; Zhang, F.; Wang, X.; Cao, H. Crosstalk between the gut microbiota and postmenopausal osteoporosis: Mechanisms and applications. Int. Immunopharmacol. 2022, 110, 108998. [Google Scholar] [CrossRef]
- Liang, X.; Wang, L. The Mediating Role of Bioactive Molecules in Gut Microbiota-Bone Metabolism Crosstalk. Nutrients 2025, 17, 3421. [Google Scholar] [CrossRef]
- Zaiss, M.M.; Jones, R.M.; Schett, G.; Pacifici, R. The gut-bone axis: How bacterial metabolites bridge the distance. J. Clin. Investig. 2019, 129, 3018–3028. [Google Scholar] [CrossRef] [PubMed]
- Ao, M.; Li, X.; Xiao, C.; Liu, Y.; Zhang, Y.; Chen, R. Role of the gut microbiota in the pathogenesis and therapeutic approach to osteoporosis (Review). Biomed. Rep. 2026, 24, 16. [Google Scholar] [CrossRef]
- Xue, K.; Tao, R.; Wu, Q.; Zhang, L.; Sun, Z.; Yu, X.; Meng, J.; Bao, N.; Zhao, J. Enteropathogenic Escherichia coli Mediates CoCrMo Particle-Induced Peri-Implant Osteolysis by Increasing Peripheral 5-HT. Front. Cell. Infect. Microbiol. 2021, 11, 796679. [Google Scholar] [CrossRef]
- Rath, S.; Heidrich, B.; Pieper, D.H.; Vital, M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome 2017, 5, 54. [Google Scholar] [CrossRef]
- Rettedal, E.A.; Ilesanmi-Oyelere, B.L.; Roy, N.C.; Coad, J.; Kruger, M.C. The gut microbiome is altered in postmenopausal women with osteoporosis and osteopenia. JBMR PLUS 2021, 5, e10452. [Google Scholar] [CrossRef] [PubMed]
- Ying, Z.-H.; Mao, C.-L.; Xie, W.; Yu, C.-H. Postbiotics in rheumatoid arthritis: Emerging mechanisms and intervention perspectives. Front. Microbiol. 2023, 14, 1290015. [Google Scholar] [CrossRef] [PubMed]
- Piccioni, A.; Rosa, F.; Manca, F.; Pignataro, G.; Zanza, C.; Savioli, G.; Covino, M.; Ojetti, V.; Gasbarrini, A.; Franceschi, F.; et al. Gut Microbiota and Clostridium difficile: What We Know and the New Frontiers. Int. J. Mol. Sci. 2022, 23, 13323. [Google Scholar] [CrossRef]
- Song, M.; Zhang, X.; Hao, G.; Lin, H.; Sun, S. Clostridium butyricum Can Promote Bone Development by Regulating Lymphocyte Function in Layer Pullets. Int. J. Mol. Sci. 2023, 24, 1457. [Google Scholar] [CrossRef]
- Zemanova, N.; Omelka, R.; Mondockova, V.; Kovacova, V.; Martiniakova, M. Roles of Gut Microbiome in Bone Homeostasis and Its Relationship with Bone-Related Diseases. Biology 2022, 11, 1402. [Google Scholar] [CrossRef]
- Yan, Q.; Cai, L.; Guo, W. New advances in improving bone health based on specific gut microbiota. Front. Cell. Infect. Microbiol. 2022, 12, 821429. [Google Scholar] [CrossRef] [PubMed]
- Okoro, P.C.; Orwoll, E.S.; Huttenhower, C.; Morgan, X.; Kuntz, T.M.; McIver, L.J.; Dufour, A.B.; Bouxsein, M.L.; Langsetmo, L.; Farsijani, S.; et al. A two-cohort study on the association between the gut microbiota and bone density, microarchitecture, and strength. Front. Endocrinol. 2023, 14, 1237727. [Google Scholar] [CrossRef]
- Magne, F.; Gotteland, M.; Gauthier, L.; Zazueta, A.; Pesoa, S.; Navarrete, P.; Balamurugan, R. The firmicutes/bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients? Nutrients 2020, 12, 1474. [Google Scholar] [CrossRef]
- Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016, 7, 189–200. [Google Scholar] [CrossRef] [PubMed]
- Zulfiqar, Z.; Huang, S.; Shi, Y. Dietary fiber derived short-chain fatty acids as a critical driver of the gut-bone axis in animal bone health: A review. Anim. Nutr. 2025, 22, 242–258. [Google Scholar] [CrossRef]
- Lawenius, L.; Gustafsson, K.L.; Wu, J.; Nilsson, K.H.; Movérare-Skrtic, S.; Schott, E.M.; Soto-Girón, M.J.; Toledo, G.V.; Sjögren, K.; Ohlsson, C. Development of a synbiotic that protects against ovariectomy-induced trabecular bone loss. Am. J. Physiol. Endocrinol. Metab. 2022, 322, E344–54. [Google Scholar] [CrossRef]
- Barone, M.; D’Amico, F.; Brigidi, P.; Turroni, S. Gut microbiome-micronutrient interaction: The key to controlling the bioavailability of minerals and vitamins? Biofactors 2022, 48, 307–314. [Google Scholar] [CrossRef] [PubMed]
- Fleet, J.C. Vitamin D-Mediated Regulation of Intestinal Calcium Absorption. Nutrients 2022, 14, 3351. [Google Scholar] [CrossRef] [PubMed]
- Bellissimo, M.P.; Roberts, J.L.; Jones, D.P.; Liu, K.H.; Taibl, K.R.; Uppal, K.; Weitzmann, M.N.; Pacifici, R.; Drissi, H.; Ziegler, T.R.; et al. Metabolomic Associations with Serum Bone Turnover Markers. Nutrients 2020, 12, 3161. [Google Scholar] [CrossRef]
- Su, S.; Tian, L. Association Between Dietary Tryptophan Intake and Bone Health: A Cross-Sectional Study. Calcif. Tissue Int. 2024, 116, 6. [Google Scholar] [CrossRef]
- Bandeira, L.; Lewiecki, E.M. Anabolic therapy for osteoporosis: Update on efficacy and safety. Arch. Endocrinol. Metab. 2022, 66, 707–716. [Google Scholar] [CrossRef]
- Piazzesi, A.; Pane, S.; Russo, A.; Del Chierico, F.; Francalanci, P.; Cotugno, N.; Rossi, P.; Locatelli, F.; Palma, P.; Putignani, L. Case Report: The impact of severe cryptosporidiosis on the gut microbiota of a pediatric patient with CD40L immunodeficiency. Front. Cell. Infect. Microbiol. 2023, 13, 1281440. [Google Scholar] [CrossRef]
- Inchingolo, F.; Inchingolo, A.M.; Piras, F.; Ferrante, L.; Mancini, A.; Palermo, A.; Inchingolo, A.D.; Dipalma, G. The interaction between gut microbiome and bone health. Curr. Opin. Endocrinol. Diabetes Obes. 2024, 31, 122–130. [Google Scholar] [CrossRef]
- Yang, K.; Qiu, X.; Cao, L.; Qiu, S. The role of melatonin in the development of postmenopausal osteoporosis. Front. Pharmacol. 2022, 13, 975181. [Google Scholar] [CrossRef]
- Torres, H.M.; Arnold, K.M.; Oviedo, M.; Westendorf, J.J.; Weaver, S.R. Inflammatory processes affecting bone health and repair. Curr. Osteoporos. Rep. 2023, 21, 842–853. [Google Scholar] [CrossRef]
- Actis, L.; Srinivasan, A.; Lopez-Ribot, J.L.; Ramasubramanian, A.K.; Ong, J.L. Effect of silver nanoparticle geometry on methicillin susceptible and resistant Staphylococcus aureus, and osteoblast viability. J. Mater. Sci. Mater. Med. 2015, 26, 215. [Google Scholar] [CrossRef]
- Malcomson, F.C.; Breininger, S.P.; ElGendy, K.; Joel, A.; Ranathunga, R.; Hill, T.R.; Bradburn, D.M.; Turnbull, D.M.; Greaves, L.C.; Mathers, J.C. Design and baseline characteristics of the Biomarkers Of Risk In Colorectal Cancer (BORICC) Follow-Up study: A 12+ years follow-up. Nutr. Health 2019, 25, 231–238. [Google Scholar] [CrossRef]
- Lau, W.L.; Savoj, J.; Nakata, M.B.; Vaziri, N.D. Altered microbiome in chronic kidney disease: Systemic effects of gut-derived uremic toxins. Clin. Sci. 2018, 132, 509–522. [Google Scholar] [CrossRef] [PubMed]
- Vong, L.; Lorentz, R.J.; Assa, A.; Glogauer, M.; Sherman, P.M. Probiotic Lactobacillus rhamnosus inhibits the formation of neutrophil extracellular traps. J. Immunol. 2014, 192, 1870–1877. [Google Scholar] [CrossRef] [PubMed]
- Bungau, S.G.; Behl, T.; Singh, A.; Sehgal, A.; Singh, S.; Chigurupati, S.; Vijayabalan, S.; Das, S.; Palanimuthu, V.R. Targeting probiotics in rheumatoid arthritis. Nutrients 2021, 13, 3376. [Google Scholar] [CrossRef]
- Harahap, I.A.; Suliburska, J. Probiotics and isoflavones as a promising therapeutic for calcium status and bone health: A narrative review. Foods 2021, 10, 2685. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Wang, X.; Zhang, C.; Liu, Z.; Li, C.; Ren, Z. Gut microbiota and bone diseases: A growing partnership. Front. Microbiol. 2022, 13, 877776. [Google Scholar] [CrossRef]
- Siddiqui, R.; Makhlouf, Z.; Alharbi, A.M.; Alfahemi, H.; Khan, N.A. The gut microbiome and female health. Biology 2022, 11, 1683. [Google Scholar] [CrossRef]
- He, Y.; Chen, Y. The potential mechanism of the microbiota-gut-bone axis in osteoporosis: A review. Osteoporos. Int. 2022, 33, 2495–2506. [Google Scholar] [CrossRef]
- Sugiyama, T. Effects of High-Dose Vitamin D Supplementation on Bone Fragility. J. Bone Miner. Res. 2020, 36, 621. [Google Scholar] [CrossRef]
- Deandra, F.A.; Ketherin, K.; Rachmasari, R.; Sulijaya, B.; Takahashi, N. Probiotics and metabolites regulate the oral and gut microbiome composition as host modulation agents in periodontitis: A narrative review. Heliyon 2023, 9, e13475. [Google Scholar] [CrossRef]
- Cheng, J.; Zhai, J.; Zhong, W.; Zhao, J.; Zhou, L.; Wang, B. Lactobacillus rhamnosus GG Promotes Intestinal Vitamin D Absorption by Upregulating Vitamin D Transporters in Senile Osteoporosis. Calcif. Tissue Int. 2022, 111, 162–170. [Google Scholar] [CrossRef] [PubMed]
- Pugh, J.N.; Lydon, K.M.; O’Donovan, C.M.; O’Sullivan, O.; Madigan, S.M. More than a gut feeling: What is the role of the gastrointestinal tract in female athlete health? Eur. J. Sport Sci. 2022, 22, 755–764. [Google Scholar] [CrossRef] [PubMed]
- Zeng, W.; Yang, F.; Shen, W.L.; Zhan, C.; Zheng, P.; Hu, J. Interactions between central nervous system and peripheral metabolic organs. Sci. China Life Sci. 2022, 65, 1929–1958. [Google Scholar] [CrossRef]
- Ibrahim, I.; Syamala, S.; Ayariga, J.A.; Xu, J.; Robertson, B.K.; Meenakshisundaram, S.; Ajayi, O.S. Modulatory Effect of Gut Microbiota on the Gut-Brain, Gut-Bone Axes, and the Impact of Cannabinoids. Metabolites 2022, 12, 1247. [Google Scholar] [CrossRef] [PubMed]
- Vallianou, N.G.; Geladari, E.; Kounatidis, D. Microbiome and hypertension: Where are we now? J. Cardiovasc. Med. 2020, 21, 83–88. [Google Scholar] [CrossRef]
- Santisteban, M.M.; Kim, S.; Pepine, C.J.; Raizada, M.K. Brain-Gut-Bone Marrow Axis: Implications for Hypertension and Related Therapeutics. Circ. Res. 2016, 118, 1327–1336. [Google Scholar] [CrossRef]
- Zhu, S.; Yan, M.-Q.; Masson, A.; Chen, W.; Li, Y.-P. Cell signaling and transcriptional regulation of osteoclast lineage commitment, differentiation, bone resorption and diseases. Cell Discov. 2026, 12, 6. [Google Scholar] [CrossRef]
- Liu, S.; Li, C.; Lv, Y.; Xue, S.; Zhao, K.; Chang, H.; Zhao, H.; Jin, B.; Ding, A.; Zhao, Y. Butyrate-producing Lactococcus lactis-fermented goat cheese enhances bone health and reduces osteoporotic bone loss. J. Dairy Sci. 2025, 108, 9048–9061. [Google Scholar] [CrossRef]
- Hiratai, R.; Nakamura, M.; Yamashita, K. Role of collagen and inorganic components in electrical polarizability of bone. J. Vet. Med. Sci. 2014, 76, 205–210. [Google Scholar] [CrossRef]
- Zhao, T.; Huang, Y.; Zhu, J.; Qin, Y.; Wu, H.; Yu, J.; Zhai, Q.; Li, S.; Qin, X.; Wang, D.; et al. Extracellular matrix signaling cues: Biological functions, diseases, and therapeutic targets. MedComm 2025, 6, e70281. [Google Scholar] [CrossRef]
- Ke, K.; Arra, M.; Abu-Amer, Y. Mechanisms Underlying Bone Loss Associated with Gut Inflammation. Int. J. Mol. Sci. 2019, 20, 6323. [Google Scholar] [CrossRef] [PubMed]
- Li, R.; Zhou, R.; Wang, H.; Li, W.; Pan, M.; Yao, X.; Zhan, W.; Yang, S.; Xu, L.; Ding, Y.; et al. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. Cell Death Differ. 2019, 26, 2447–2463. [Google Scholar] [CrossRef]
- Lorenzo, D.; GianVincenzo, Z.; Carlo Luca, R.; Karan, G.; Jorge, V.; Roberto, M.; Javad, P. Oral-Gut Microbiota and Arthritis: Is There an Evidence-Based Axis? J. Clin. Med. 2019, 8, 1753. [Google Scholar]
- Forte, Y.S.; Renovato-Martins, M.; Barja-Fidalgo, C. Cellular and molecular mechanisms associating obesity to bone loss. Cells 2023, 12, 521. [Google Scholar] [CrossRef]
- Williams, K.L.; Enslow, R.; Suresh, S.; Beaton, C.; Hodge, M.; Brooks, A.E. Using the microbiome as a regenerative medicine strategy for autoimmune diseases. Biomedicines 2023, 11, 1582. [Google Scholar] [CrossRef] [PubMed]
- Schiellerup, S.P.; Skov-Jeppesen, K.; Windeløv, J.A.; Svane, M.S.; Holst, J.J.; Hartmann, B.; Rosenkilde, M.M. Gut hormones and their effect on bone metabolism. potential drug therapies in future osteoporosis treatment. Front. Endocrinol. 2019, 10, 75. [Google Scholar] [CrossRef]
- Kwon, Y.; Park, C.; Lee, J.; Park, D.H.; Jeong, S.; Yun, C.-H.; Park, O.-J.; Han, S.H. Regulation of Bone Cell Differentiation and Activation by Microbe-Associated Molecular Patterns. Int. J. Mol. Sci. 2021, 22, 5805. [Google Scholar] [CrossRef]
- Kuchay, M.S.; Choudhary, N.S.; Mishra, S.K. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab. Syndr. 2020, 14, 1875–1887. [Google Scholar] [CrossRef]
- Wang, Y.; Ze, X.; Rui, B.; Li, X.; Zeng, N.; Yuan, J.; Li, W.; Yan, J.; Li, M. Studies and application of sialylated milk components on regulating neonatal gut microbiota and health. Front. Nutr. 2021, 8, 766606. [Google Scholar] [CrossRef]


| Probiotic Strain | Effect on Bone Health | Metabolic Pathways and Metabolites | References |
|---|---|---|---|
| Lactobacillus rhamnosus GG | Improves gut barrier health, prevents TNF- induced mucosal damage, enhances calcium absorption. | Enhances mucin expression, produces SCFAs increasing calcium solubility and absorption. Protein HM0539 involved. | See Table 2 |
| Lactobacillus casei Shirota | Enhances gut health, reduces inflammation, improves fracture healing, reduces osteoarthritis biomarkers. | Produces low molecular weight metabolites, increases IL-10, reduces TNF-, IL-6, and IL-12, aiding in anti-inflammatory effects. | [45,70] |
| Bacillus subtilis C-3102 | Increases BMD, inhibits bone resorption, improves calcium absorption. | Increases uNTx and TRACP-5b, enhances gut microbiota, increases butyrate production which supports osteoblast proliferation and differentiation. | [69,70,71] |
| Lactobacillus reuteri ATCCPTA 6475 | Reduces BMD loss in older women. | Modulates gut microbiota, suppresses the expression of pro-inflammatory and pro-osteoclastogenic cytokines reducing bone resorption. | [69] |
| Lactobacillus plantarum GKM3 and DSM 15312 | Inhibits bone loss, promotes osteogenesis, decreases osteoclastogenesis. | Produces SCFAs, regulates VDR and TRPV6 for calcium absorption, modulates claudin-2 for intestinal permeability. | [69] |
| Lactobacillus paracasei DSM 13434 | Protects against rapid BMD loss in postmenopausal women. | Produces SCFAs, reduces intestinal permeability, decreases pro-inflammatory cytokines like TNF-. | [69] |
| Lactobacillus intestinalis YT2 | Alleviates menopausal symptoms, including bone density loss. | Restores gut microbiota composition, enhancing overall gut health and indirectly supporting bone health. | [71] |
| Lactobacillus plantarum NK3 | Alleviates bacterial vaginosis and osteoporosis. | Suppresses NF-κB/TNF- pathway, reducing inflammation and promoting bone health. | [72] |
| Lactobacillus reuteri NCIMB 30242 | Increases serum vitamin D levels, crucial for bone health. | Increases circulating 25-hydroxyvitamin D, supporting bone mineralization and health. | [72] |
| Bifidobacterium lactis Probio-M8 | Improves bone metabolism, increases vitamin D3, decreases PTH and procalcitonin, enhances calcium absorption. | Involves carbohydrate metabolism pathways, enhances gut microbial interactions, increases SCFA-producing bacteria and choline-phosphate cytidylyltransferase. | [73] |
| Streptococcus salivarius W24 | Inhibits periodontopathogens, maintains immune homeostasis. | Targets IL-6 and IL-8 pathways, producing bacteriocins that suppress pathogen growth. | [71] |
| Tenericutes ML615J-28, 124-7 | Reduction in abundance in Polycystic Ovary Syndrome (PCOS) patients, potentially improves bone health. | Specific metabolic pathways not clearly defined, but reduction in abundance correlates with improved bone health. | [71] |
| Bifidobacterium lactis HN019 | Reduces IL-1, RANKL-OPG ratio, TNF-, and IL-6, disrupts Gram-negative bacteria membrane, reduces P. gingivalis adhesion. | Regulates the immune system through organic acids like lactic acid, contributing to anti-inflammatory effects. | [74] |
| Metabolic Pathways and Involved Metabolites | Effects on Bone Health | How LGG Influences | References |
|---|---|---|---|
| Production of SCFAs (Butyrate, propionate, acetate) | Promotes the differentiation of mesenchymal stem cells into osteoblasts, improves bone formation, and reduces bone resorption. | Increases the production of SCFAs, especially butyrate, which activates the Wnt/-catenin pathway and reduces inflammation by inhibiting NF-κB. | [38,48,60,68,72,73] |
| Wnt/-catenin (Butyrate) | Stimulates the accumulation of -catenin, promoting the proliferation and differentiation of stem cells into osteoblasts. | Increases the production of butyrate, which activates the Wnt/-catenin pathway to promote bone formation. | [38,73] |
| NF-B (Butyrate) | Reduces inflammation, creating a favorable environment for bone formation by inhibiting osteoclast activation. | Producing butyrate, inhibits NF-κB signaling, which decreases inflammation and protects bone mass. | [38,72,73] |
| -D-glucuronidase (Estrogens) | Regulates estrogen levels, essential for maintaining bone density in postmenopausal women. | Reduces -D-glucuronidase activity, limiting estrogen reabsorption and reducing the risk of reproductive cancers, maintaining a healthy estrogen balance. | [38,48,73] |
| Tryptophan Metabolism (Indoles) | Modulates the immune system, decreases inflammation, and supports bone health. | Metabolizes tryptophan to produce indoles, which have anti-inflammatory effects and contribute to beneficial immune modulation for bone health. | [60] |
| Glycolysis (Lactate) | Maintains a healthy intestinal environment that indirectly supports bone health. | Produces lactate through glycolysis, helping maintain an appropriate intestinal pH, favoring the presence of beneficial bacteria that support bone health. | [60] |
| Vitamin D Absorption (Vitamin D) | Improves calcium absorption, essential for bone mineralization and overall bone health. | Increases the expression of the vitamin D receptor in intestinal cells, improving calcium absorption. | [68] |
| Immune Modulation (IL-10, TGF-) | Decreases osteoclast activity and promotes bone formation by increasing the production of anti-inflammatory cytokines. | Promotes the expansion of Treg cells that secrete IL-10 and TGF-, modulating the immune response to protect against bone loss. | [38,60,72,73] |
| Strengthening of the Intestinal Barrier (SCFAs, Butyrate) | Strengthens the intestinal barrier, reduces intestinal permeability, and protects against systemic inflammation that negatively affects bone health. | Produces SCFAs like butyrate, which improves intestinal barrier function, reducing endotoxin translocation and systemic inflammation. | [38,60,72] |
| Regulation of Osteoprotegerin (OPG) | Inhibits osteoclast formation and reduces bone resorption, promoting bone formation. | Increases the expression of OPG, a decoy receptor that blocks the interaction of RANKL with RANK, thus decreasing osteoclastic activity. | [60] |
| Metabolic Pathway | Effect and Relation with the Gut–Brain–Bone Axis | Participating Microbiota | References |
|---|---|---|---|
| RANKL and TRAP5 Pathways | Inhibition of these pathways by butyrate reduces osteoclastogenesis, promotes bone formation, improves bone mineral density, and reduces bone loss. | Lactobacillus reuteri, Lactobacillus plantarum, Lactobacillus paracasei | [76] |
| Anti-Inflammatory Pathways | SCFAs (butyrate) reduce inflammatory cytokines (IL-6 and TNF-), improving bone and brain health by reducing systemic inflammation. | Lactobacillus reuteri, Bifidobacterium longum, Faecalibacterium prausnitzii | [76,77] |
| Treg-Th17 Modulation | GABA and butyrate regulate the differentiation of Treg and Th17 cells, balancing the immune response, which is essential for maintaining bone and brain health. | Lactobacillus rhamnosus (JB-1) | [77,78] |
| IGF-1 Signaling Pathway | SCFAs enhance IGF-1 signaling, promoting bone formation and growth by connecting gut and brain signaling, which improves bone density and strength. | Bifidobacterium longum, Bacteroides spp. | [79] |
| Serotonin Signaling | Serotonin regulates osteoblast and osteoclast activities, influencing bone density and quality through central and peripheral signaling, ensuring balanced bone remodeling. | Escherichia coli | [77] |
| G-protein-coupled receptors (GPCR)—GPR41, GPR43, GPR109A | SCFAs interact with GPCRs to regulate renin release and blood pressure, indirectly benefiting bone health through anti-inflammatory effects. | Lactobacillus murinus, Bacteroides spp. | [79] |
| Olfactory Receptor 78 (Olfr78) Involved metabolite: SCFAs (Propionate) | Propionate promotes vasodilation by altering Olfr78 and GPR41 activity, contributing to an acute hypotensive response and indirectly benefiting bone health. | Bacteroides spp. | [80] |
| GABA Production | GABA regulates brain function, reduces anxiety, and improves mood, indirectly benefiting bone health by reducing stress-related bone loss. | Lactobacillus rhamnosus (JB-1), Streptococcus thermophilus | [78,79] |
| Osteocalcin Production | Osteocalcin, along with vitamin K and SCFAs, directly influences bone formation and homeostasis, preventing fractures and maintaining bone health. | Lactobacillus reuteri, Bacteroides spp., Faecalibacterium prausnitzii | [76,77,78] |
| Neuromodulator Production | Neurotransmitters like serotonin and dopamine regulate mood and behavior, impacting bone health by influencing the stress response and ensuring balanced bone remodeling. | Escherichia coli, Lactobacillus spp. | [78] |
| Dietary Fiber Fermentation | SCFAs produced during fiber fermentation regulate inflammation, improve intestinal permeability, and enhance calcium absorption, all critical for bone health. | Faecalibacterium prausnitzii, Bacteroides spp., Lactobacillus spp., Clostridium spp. | [77,79] |
| Corticotropin (CRH) Signaling | CRH plays a key role in regulating the stress response, with chronic stress negatively affecting both brain and bone health. SCFAs and other metabolites help mitigate these effects. | Lactobacillus spp., Bifidobacterium spp., Firmicutes, Tenericutes | [76,77] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Cantón-Cordeiro, T.; Shimochi, S.; Nakamura, M.; Puigbò, P. The Gut–Bone Axis: A Systematic Review on the Potential Intervention Pathways for Bone Health. Life 2026, 16, 909. https://doi.org/10.3390/life16060909
Cantón-Cordeiro T, Shimochi S, Nakamura M, Puigbò P. The Gut–Bone Axis: A Systematic Review on the Potential Intervention Pathways for Bone Health. Life. 2026; 16(6):909. https://doi.org/10.3390/life16060909
Chicago/Turabian StyleCantón-Cordeiro, Tomás, Saeka Shimochi, Miho Nakamura, and Pere Puigbò. 2026. "The Gut–Bone Axis: A Systematic Review on the Potential Intervention Pathways for Bone Health" Life 16, no. 6: 909. https://doi.org/10.3390/life16060909
APA StyleCantón-Cordeiro, T., Shimochi, S., Nakamura, M., & Puigbò, P. (2026). The Gut–Bone Axis: A Systematic Review on the Potential Intervention Pathways for Bone Health. Life, 16(6), 909. https://doi.org/10.3390/life16060909

